Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction

被引:185
作者
DizonTomson, DS [1 ]
Meline, L [1 ]
Nelson, LM [1 ]
Warner, M [1 ]
Ward, K [1 ]
机构
[1] UNIV UTAH,SCH MED,DEPT HUMAN GENET,SALT LAKE CITY,UT 84132
关键词
factor V Leiden; miscarriage; placental infarction;
D O I
10.1016/S0002-9378(97)70205-9
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVES: The factor V Leiden mutation is the most common genetic predisposition to thrombosis. However, little is known concerning the reproductive outcome of mutation carriers or prenatal expressivity of this thrombogenic mutation. Our purpose was to examine whether this mutation presents phenotypically as miscarriage or idiopathic placental thrombosis. STUDY DESIGN: We performed two studies. First, a case-control comparison to determine whether fetal or maternal carriers of the factor V Leiden mutation are at risk for spontaneous miscarriage was performed, and, second, a cohort study evaluating placental infarction in fetuses carrying this mutation was performed. RESULTS: We found a twofold increase in the factor V Leiden carrier frequency in 12 of 139 (8.6%) abortuses compared with 17 of 403 (4.2%) unselected pregnant women seen in the labor and delivery suite and, even more remarkable, a tenfold increase in the fetal carrier frequency in 10 of 24 (42%) placentas with >10% placental infarction compared with 7 of 372 (1.9%) placentas with <10% placental infarction. CONCLUSIONS: These findings suggest a prenatal phenotype and effects of this mutation at the fetoplacental interface. if large prospective studies confirm these findings, then testing for this thrombogenic mutation should be considered in women and placental tissue from spontaneous abortuses and placentas with evidence of placental infarction. In addition to identifying individuals and families at risk for thrombosis, this information may help to improve our understanding of hemostasis and circulatory disturbances at the fetoplacental interface.
引用
收藏
页码:402 / 405
页数:4
相关论文
共 21 条
[1]  
ALTEMANI AM, 1987, PATHOL RES PRACT, V182, P685
[2]   THE ASSOCIATION OF MATERNAL FLOOR INFARCTION OF THE PLACENTA WITH ADVERSE PERINATAL OUTCOME [J].
ANDRES, RL ;
KUYPER, W ;
RESNIK, R ;
PIACQUADIO, KM ;
BENIRSCHKE, K .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1990, 163 (03) :935-938
[3]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[4]  
CASTELLUCCI M, 1995, PATHOL HUMAN PLACENT, P93
[5]  
DAHLBACK B, 1994, HAEMOSTASIS, V24, P139
[6]  
DEMIR R, 1989, ACTA ANAT, V136, P190
[7]   The incidence of the factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis [J].
DizonTownson, DS ;
Nelson, LM ;
Jang, H ;
Varner, MW ;
Ward, K .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1997, 176 (04) :883-886
[8]   The factor V Leiden mutation may predispose women to severe preeclampsia [J].
DizonTownson, DS ;
Nelson, LM ;
Easton, K ;
Ward, K .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 175 (04) :902-905
[9]   CLINICAL-SIGNIFICANCE AND TREATMENT OF MASSIVE INTERVILLOUS FIBRIN DEPOSITION ASSOCIATED WITH RECURRENT FETAL GROWTH-RETARDATION [J].
FUKE, Y ;
AONO, T ;
IMAI, S ;
SUEHARA, N ;
FUJITA, T ;
NAKAYAMA, M .
GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 1994, 38 (01) :5-9
[10]   Activated protein C resistance and pregnancy complications [J].
Grisaru, D ;
Fait, G ;
Eldor, A .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 174 (02) :801-802